The market was looking for something wildly positive in the EOA data, which was only 3 months of treatment. Since Gevo is only dispensed 1x a month, it makes sense that a full 6 months of data would give a much more complete picture of efficacy. Safety does not appear to be an issue, so that's a real positive. There's a lot to like about Gevo, but at this point it's a drug looking for a market, or markets. It will eventually succeed, IMO, but additional clinical trials will be needed to determine the best application for the drug.
And let's not forget this (EOA) was just one of a slew of indications Gevo is being investigated. No question it would have been better if they put out 2 separate PRs yesterday so as not to confuse the market. But the fact is that we got some good news (new indication) and some incomplete news yesterday.
six month is definitely necessary I think for a condition such as this for significant improvement. The trend they are seeing at 3 month is what they have reported. I am surprised why there is such a big deal about the "non reporting" of stats significance at this point. Did anybody really expect any interim news now???